Dimetacrine

Dimetacrine

SCHEMBL3501515

CN(C)CCCN1c2ccccc2C(C)(C)c2ccccc21.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Dimetacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 6/20 0.47
CHRM2 known ✓ P08172 5/20 0.47
CHRM1 known ✓ P11229 5/20 0.47
SLC6A2 known ✓ P23975 5/20 0.47
ADRA1A known ✓ P35348 5/20 0.47
OPRM1 known ✓ P35372 5/20 0.47
HTR2A known ✓ P28223 5/20 0.47
CHRM4 known ✓ P08173 4/20 0.47
ADRA2B known ✓ P18089 4/20 0.47
ADRA2C known ✓ P18825 4/20 0.47
CHRM3 known ✓ P20309 4/20 0.47
OPRK1 known ✓ P41145 4/20 0.47
ADRA2A known ✓ P08913 4/20 0.47
SLC6A3 known ✓ Q01959 4/20 0.47
ADRA1D known ✓ P25100 3/20 0.47
ADRB2 known ✓ P07550 2/20 0.47
HTR1D known ✓ P28221 1/20 0.47
ADRB1 known ✓ P08588 1/20 0.44
ADRB3 known ✓ P13945 1/20 0.42
OPRD1 known ✓ P41143 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimetacrine SCHEMBL3501514 1.00 CYP2D6 (0.75) CYP2D6CYP1A2KMT2ALMNAMAPT
Dimetacrine SCHEMBL29578094 0.87 CYP2D6 (1.00) CYP2D6CYP1A2KMT2ALMNAMAPT
Dimetacrine SCHEMBL50120 0.87 CYP2D6 (1.00) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL11640552 0.79 CYP2D6 (0.78) CYP2D6CYP1A2KMT2ALMNAMAPT
Dimetacrine SCHEMBL28221926 0.73 HRH1 (0.71) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL13231573 0.71 KMT2A (0.68) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL17739604 0.70 KMT2A (0.68) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL11640659 0.70 KMT2A (0.63) CYP2D6CYP1A2KMT2ALMNAMAPT
Imipramine SCHEMBL20644144 0.69 SLC6A4 (0.83) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL21027093 0.69 TP53 (0.51) CYP2D6CYP1A2KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8231899-B2 An orally-administered drug having low solubility in acid environment, e.g. stomach, being a powder contacted with water to form particules where >50% pass through sieve 180 mu m; in 0.07 N hydrochloric acid >50% released within 20 min.; high strength tablets; bioavailability; drug delivery NYCOMED DANMARK APS (DK) 2012-07-31 US disclosed
US-20100184033-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY Lineage Cell Therapeutics, Inc. 2010-07-22 US disclosed
US-20080226601-A1 Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods UNIVERSITY OF ROCHESTER (US) 2008-09-18 US disclosed
EP-1903873-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS THE UNIVERSITY OF ROCHESTER (US) 2008-04-02 EP disclosed
EP-1850854-A1 ROOM TEMPERATURE STABLE AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION Biomarin Pharmaceutical Inc. (US) 2007-11-07 EP disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 WO disclosed
WO-2006093493-A1 ROOM TEMPERATURE STABLE AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION BIOMARIN PHARMACEUTICAL INC. (US) 2006-09-08 WO disclosed
US-20060013834-A1 Room temperature stable aqueous liquid pharmaceutical composition MEDICIS PEDIATRICS, INC. (US) 2006-01-19 US disclosed
US-20050147668-A1 Quick release pharmaceutical compositions of drug substances NYCOMED DANMARK A/S 2005-07-07 US disclosed
US-6713089-B1 UNDER ACIDIC CONDITIONS; NONSTEROID ANTIINFLAMMATORY NSAID; CRUSHING STRENGTH NYCOMED DANMARK A/S (DK) 2004-03-30 US disclosed
EP-1017370-B1 MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) NYCOMED DANMARK APS (DK) 2003-10-29 EP disclosed
US-6599529-B1 Fast acting; sustained release NYCOMED DANMARK A/S (DK) 2003-07-29 US disclosed
EP-1109534-B1 QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES NYCOMED DANMARK AS (DK) 2003-02-12 EP disclosed
EP-1109534-A1 QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES NYCOMED DANMARK A/S (DK) 2001-06-27 EP disclosed
EP-1017370-A1 MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) NYCOMED DANMARK A/S (DK) 2000-07-12 EP disclosed
WO-2000015195-A1 QUICK RELEASE PHARMACEUTICAL COMPOSITIONS OF DRUG SUBSTANCES NYCOMED DANMARK A/S (DK) 2000-03-23 WO disclosed
WO-1999012524-A1 MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) NYCOMED DANMARK A/S (DK) 1999-03-18 WO disclosed